despite your polarizing reception on this board, that is a possible scenario. If they can't turn results into money and fast action, it's meaningless. Think if the best outcome they produce from this phase 2 is getting the drug into a government sponsored ph3 trial, shareholders will have to wait TRULY 1+ more years (12-16 months) to get the results from that trial. So, you'd be looking at summer 2022 for results from a covid phase 3, fastest case scenario. covid will be an afterthought in the sense that large % of countries will be vaccinated and other therapeutics, equally worthy, might be far ahead of ipix in development (don't fall into the great fallacy of thinking that ipix has the only therapeutic in development in the entire world that will save the world of covid). heck, other companies, even UCSF (google it) are developing similarly classed drugs as brilacidin for covid. You have to look at the Competitive Set honestly and carefully and not with googly-eyed biased rose colored glasses. IPIX needs to get $$$$ in or a deal done as soon as September or October, and they need to bypass the Phase 3 requirement. The pressure is on IPIX management. Their track record is not confidence inducing (its actually pathetic) but fortunately Locust Walk is steering their ship according to PRs.
News 
Market Data 
Discover 
